Table 1 Comparison of patient characteristics between CCLG and GPOH
Number of patients (percentage) | p value | ||
|---|---|---|---|
CCLG | GPOH | ||
N = 210 | N = 437 | ||
Gender | |||
Female | 84 (40) | 177 (40) | 0.90 |
Male | 126 (60) | 260 (60) | |
Age (approx quartiles) (years) | |||
0–9 | 34 (16) | 94 (22) | 0.17 |
10–14 | 74 (35) | 123 (28) | |
15–19 | 58 (28) | 115 (26) | |
20–35 | 44 (21) | 105 (24) | |
Primary site | |||
Central axis | 84 (40) | 236 (54) | < 0.001 (0.004) |
Extremity | 115 (55) | 197 (45) | |
Unknown | 11 (5) | 4 (1) | |
Axial skeletal | 26 (12) | 89 (20) | |
Spine | 7 (3 | 30 (7) | |
Pelvis | 51 (24) | 117 (27) | |
Limb proximal | 61 (29) | 103 (23) | |
Limb distal | 54 (26) | 94 (22) | |
Unknown | 11 (5) | 4 (1) | |
Volume | |||
< 100 ml | 57 (27) | 117 (27) | 0.48 (0.97) |
≥ 100 ml | 149 (71) | 304 (69) | |
Unknown | 4 (2) | 16 (4) | |
Metastases | |||
No | 150 (71) | 329 (75) | 0.27 (0.41) |
Yesd | 56 (27) | 105 (24) | |
Unknown | 4 (2) | 3 (1) | |
Histology | |||
Ewing’s sarcoma | 140 (67) | 261 (60) | < 0.001 (< 0.001) |
Atypical Ewing’s | 8 (4) | 70 (16) | |
PNET | 43 (20) | 101 (23) | |
Othera | 6 (3) | 5 (1) | |
Unknown | 13 (6) | 0 (0) | |
Risk group | |||
Standard (SR) | 53 (25) | 102 (23) | 0.60 |
High (HR) | 157 (75) | 335 (77) | |
Trial treatment | |||
SR-VACA | 27 (13) | 52 (12) | 0.96 |
SR-VAIA | 26 (12) | 50 (11) | |
HR-VAIA | 76 (36) | 164 (38) | |
HR-EVAIA | 81 (39) | 171 (39) | |
Histological responsec | |||
Good | 52 (25) [58] | 78 (18) [65] | < 0.001 [0.33] |
Poor | 37 (18) [42] | 42 (10) [35] | |
No surgery | 103 (49) | 111 (25) | |
NAb | 3 (1) | 200 (46) | |
Unknown | 15 (7) | 6 (1) | |
No. of chemotherapy cycles received | |||
1–4 | 18 (8.6) | 26 (6.0) | 0.32 |
5–9 | 22 (10.5) | 62 (14.2) | |
10–13 | 36 (17.10 | 83 (19.0) | |
14 | 131 (62.4) | 254 (58.2) | |
Unknown | 3 (1.4) | 12 (2.8) | |